Stanford, California 94305

  • Liver Cancer

Purpose:

The aim of the study is to see if there any changes in the quality of life for patients that are undergoing radical prostatectomy.


Study summary:

Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer that can be used to increase the rate of accurate diagnosis of this malignancy.


Criteria:

Inclusion Criteria:Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer. Exclusion Criteria:Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.


NCT ID:

NCT00373347


Primary Contact:

Principal Investigator
Samuel So
Stanford University

Mei-Sze Chua
Phone: 650-724-3525
Email: mchua@stanford.edu


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States

Mei-Sze Chua
Phone: 650-724-3525
Email: mchua@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 26, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.